APA

Koppe M., Schaijk F. v., Roos J., Leeuwen P. v., Heider K., Kuthan H. & Bleichrodt R. (20050526). Safety, pharmacokinetics, immunogenicity, and biodistribution of (186)Re-labeled humanized monoclonal antibody BIWA 4 (Bivatuzumab) in patients with early-stage breast cancer. : Cancer biotherapy & radiopharmaceuticals.

Chicago

Koppe Manuel, Schaijk Frank van, Roos Jan, Leeuwen Paul van, Heider Karl-Heinz, Kuthan Hartmut and Bleichrodt Robert. 20050526. Safety, pharmacokinetics, immunogenicity, and biodistribution of (186)Re-labeled humanized monoclonal antibody BIWA 4 (Bivatuzumab) in patients with early-stage breast cancer. : Cancer biotherapy & radiopharmaceuticals.

Harvard

Koppe M., Schaijk F. v., Roos J., Leeuwen P. v., Heider K., Kuthan H. and Bleichrodt R. (20050526). Safety, pharmacokinetics, immunogenicity, and biodistribution of (186)Re-labeled humanized monoclonal antibody BIWA 4 (Bivatuzumab) in patients with early-stage breast cancer. : Cancer biotherapy & radiopharmaceuticals.

MLA

Koppe Manuel, Schaijk Frank van, Roos Jan, Leeuwen Paul van, Heider Karl-Heinz, Kuthan Hartmut and Bleichrodt Robert. Safety, pharmacokinetics, immunogenicity, and biodistribution of (186)Re-labeled humanized monoclonal antibody BIWA 4 (Bivatuzumab) in patients with early-stage breast cancer. : Cancer biotherapy & radiopharmaceuticals. 20050526.